Cytokine profile and proteolytic enzyme levels in plasma of patients with chronic cerebral ischemia following COVID-19
Open Access
- 20 May 2025
- journal article
- Published by Publishing House Zaslavsky in INTERNATIONAL NEUROLOGICAL JOURNAL
- Vol. 21 (3) , 169-175
Abstract
Background. The purpose of this study was to determine the cytokine profile, levels of proteolytic enzymes, and the TIMP-1 in the plasma of patients with chronic cerebral ischemia (CCI) following symptomatic COVID-19, considering gender differences. Materials and methods. The research involved 108 patients with CCI aged 43 to 74 years, including 56 patients who had been diagnosed with COVID-19 in the past 9–12 months (CCI and COVID-19 group) and 52 patients with no history of SARS-CoV-2 infection (CCI group). The participants were also stratified by gender. Plasma levels of cytokines (IL-1, IL-4, IL-6, IL-8, IL-17, IL-18R, TNF-, and IFN-), matrix metalloproteinases (MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, and MMP-10), and TIMP-1 were measured using enzyme-linked immunosorbent assay. Results. No significant differences were revealed in the levels of most cytokines in the plasma of CCI patients with and without a history of COVID-19, except for IL-1, which was elevated by 46.65 % in female CCI patients who had experienced symptomatic COVID-19. Higher levels of proteolytic enzymes MMP-1, MMP-2, and MMP-12 were found in the plasma of male CCI patients who recovered from COVID-19, with increases of 20.72, 27.33, and 20.37 %, respectively, compared to participants with no history of SARS-CoV-2 infection. No significant differences in TIMP-1 levels were observed between the CCI and CCI and COVID-19 groups. The obtained data may indicate gender-specific changes in the cytokine profile and proteolytic system in CCI patients following symptomatic COVID-19. Conclusions. SARS-CoV-2 infection, even after a long post-acute period, can activate alternative pathogenetic mechanisms, including dysregulation of cytokine, systemic inflammation, and proteolytic imbalance with gender-specific characteristics, which may exacerbate ischemic processes in patients with CCI and increase the risk of cerebrovascular complications.Keywords
This publication has 30 references indexed in Scilit:
- Gender Disparities in Neurological Symptoms of Long COVID: A Systematic Review and Meta-AnalysisNeuroepidemiology, 2024
- The impact of cytokines in neuroinflammation-mediated strokeCytokine & Growth Factor Reviews, 2024
- Implications of MMP-12 in the pathophysiology of ischaemic strokeStroke and Vascular Neurology, 2023
- Projected Global Trends in Ischemic Stroke Incidence, Deaths and Disability-Adjusted Life Years From 2020 to 2030Stroke, 2023
- Neurological manifestations by sex and age group in COVID-19 inhospital patientseNeurologicalSci, 2022
- The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19Cell Reports Medicine, 2022
- Matrix metalloproteinases are involved in the development of neurological complications in patients with Coronavirus disease 2019International Immunopharmacology, 2021
- Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019The Lancet Neurology, 2021
- MMP-2 and MMP-9 levels in plasma are altered and associated with mortality in COVID-19 patientsBiomedicine & Pharmacotherapy, 2021
- SARS-CoV-2, More than a Respiratory Virus: Its Potential Role in NeuropathogenesisACS Chemical Neuroscience, 2020